Novel hormone therapies for advanced prostate cancer: understanding and countering drug resistance

doi: 10.1016/j.jpha.2025.101232

• Zhipeng Wang¹ , 
• Jie Wang² , 
• Dengxiong Li² , 
• Ruicheng Wu² , 
• Jianlin Huang¹ , 
• Luxia Ye³ , 
• Zhouting Tuo⁴ , 
• Qingxin Yu⁵ , 
• Fanglin Shao⁶ , 
• Dilinaer Wusiman^7,8 , 
• William C. Cho⁹ , 
• Siang Boon Koh^{10 ,  ,}  , 
• Wei Xiong^{1 ,  ,}  , 
• Dechao Feng^{11 ,  ,} 

• 1. Department of Urology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China;

• 2. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China;

• 3. Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Taizhou, 317000, China;

• 4. Department of Urological Surgery, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing, 400042, China;

• 5. Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ningbo City, Zhejiang Province, 315211, China;

• 6. Department of Rehabilitation, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China;

• 7. Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, IN, 47907, USA;

• 8. Purdue Institute for Cancer Research, Purdue University, West Lafayette, IN, 47907, USA;

• 9. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, 999077, China;

• 10. Faculty of Health and Life Sciences, University of Bristol, Bristol, BS8 1TD, UK;

• 11. Division of Surgery & Interventional Science, University College London, London W1W 7TS, UK